Möchten Sie immer auf dem neuesten Stand bleiben?

Second trial showing mGluR5 inhibition reduces reflux in humans Side effects dramatically reduced by formulation Twice-daily oral dosing achieved Doses selected for Phase IIb trials Phase...

Geneva, Switzerland, 7 August 2008 - Addex Pharmaceuticals (SWX:ADXN) announced today that on August 6, 2008, Varuma AG, Aeschenvorstadt 55, 4051 Basel, Switzerland, has informed of exceeding the...

  Geneva, Switzerland, 5 August 2008 - Addex Pharmaceuticals (SWX:ADXN) announced today that on July 31, 2008, The Swiss Helvetia Fund, Inc. 1270 Avenue of the Americas, Suite 400, New York, NY...

Français (PDF)    Deutsch (PDF)  English (PDF)  Geneva, Switzerland, 28 July 2008 - Addex Pharmaceuticals (SWX:ADXN) released today financial results for the first...

Français (PDF)  Deutsch (PDF)  English (PDF)    Geneva, Switzerland, 28 July 2008 - Addex Pharmaceuticals is pleased to announce the appointment of Laurent Galibert to its...

  Geneva, Switzerland, 18 July 2008 - Addex Pharmaceuticals Ltd. (SWX:ADXN) will discuss its financial results for the first half of 2008 and give a pipeline update during a teleconference and...

New formulation of ADX10059 selected   German PDF French PDF English PDF Geneva, Switzerland, 4 June 2008 - Addex Pharmaceuticals (SWX:ADXN) announced that it has started Study...

Geneva, Switzerland, 27 May 2008 - Addex Pharmaceuticals Ltd. (SWX:ADXN) disclosed the following shareholdings. Addex Pharmaceuticals Ltd. was informed by: Sofinnova Capital IV FCPR(1)...

Geneva, Switzerland, 24 April 2008 - Addex Pharmaceuticals (SWX:ADXN) announced that it has begun Phase I testing of two formulations of ADX10059 and that it will elaborate on ADX10059 development and...

  Shareholders Approve All Board Proposals at 2008 AGMGeneva, Switzerland, 18 April 2008 - Addex Pharmaceuticals Ltd. (SWX:ADXN) announced that its shareholders approved all the proposals of...